Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

VIA Disc NP Pilot for Patients With Symptomatic Degenerated Discs

NCT05201287 · View on ClinicalTrials.gov ↗

Study Summary

VIA Disc NP is an allograft intended to supplement the nucleus pulposus tissue in degenerated intervertebral discs.

Interventions

  • OTHER VIA Disc NP

Study Locations (6)

California

  • California Orthopedics and Spine — Larkspur
  • Source Health — Santa Monica
  • IPM Medical Group — Walnut Creek

Ohio

  • Cleveland Clinic — Cleveland

Oklahoma

  • Clinical Investigations, LLC — Edmond

Virginia

  • Virginia iSpine — Richmond

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2021-12-30
Est. Completion 2024-12-27
Phase NA

Sponsor

VIVEX Biologics

4 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05201287

The ClinicalTrials.gov registry entry for NCT05201287 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VIVEX Biologics, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Low Back Pain appearing as the primary indexed condition, and to 1 intervention — of which VIA Disc NP is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05201287 reports 6 study locations spanning 4 distinct geographic areas — top geographies include California, Ohio, Oklahoma. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05201287 about?

NCT05201287 is a clinical study titled "VIA Disc NP Pilot for Patients With Symptomatic Degenerated Discs". VIA Disc NP is an allograft intended to supplement the nucleus pulposus tissue in degenerated intervertebral discs.

What is the current status of trial NCT05201287?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 35 participants. The study started on 2021-12-30. Estimated completion is 2024-12-27.

What conditions does trial NCT05201287 study?

This clinical trial studies the following conditions: Low Back Pain, Degenerative Disc Disease, Disc Degeneration. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05201287?

The interventions under investigation include: VIA Disc NP (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05201287?

This trial is sponsored by VIVEX Biologics, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05201287 being conducted?

This trial has 6 study locations across California, Ohio, Oklahoma, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial